14 July 2025
Pharmaceutics Webinar | Development of Physiologically Based Pharmacokinetic and Biopharmaceutics Analysis and Modeling (PBPK and PBBM), 22 July 2025
Physiologically Based Pharmacokinetic (PBPK) modeling involves simulating the absorption, distribution, metabolism, and excretion (ADME) of drugs throughout the body. So, PBPK modeling is a mathematical tool which can describe the drug concentration in an organism using compartments that correspond to the different tissues and takes into consideration the physiology of this organism to parameterize the model.
Physiologically Based Biopharmaceutics Modeling (PBBM) is an established analysis mechanistically linking in vitro drug product performance (like dissolution) to in vivo absorption and bioavailability.
These types of models have become useful in drug development since their discovery, and are particularly important in early phases, when in vitro data and physicochemical properties can be used to obtain plasma profiles, which would be later validated in vivo, and until the clinical development phases, in which simulations can be used to describe drug performance in special populations.
Date: 1:00 pm CEST | 7:00 am EDT | 7:00 pm CST Asia
Webinar ID: 815 2324 5665
Website: https://sciforum.net/event/Pharmaceutics-4
After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations made with academic institutional email addresses will be prioritized.
Unable to attend? Register anyway and we will let you know when the recording is available to watch online.
Register now for free!
Program:
|
Speaker/Presentation |
Time in CEST |
|
Prof. Dr. Isabel Gonzalez-Alvarez (Chair) Chair Introduction |
1:00–1:10 p.m. |
|
Dr. Bart Hens IVIVC development for a modified-release formulation using GPX™ software: impact of different deconvolution methods on dissolution safe space design |
1:10–1:40 p.m. |
|
Dr. Marival Bermejo In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan |
1:40–2:10 p.m. |
|
Dr. Yasuhiro (Hiro) Tsume PBPK modeling and PBBM analysis using GastroPlus™ |
2:10–2:40 p.m. |
|
Q&A Session |
2:40–2:50 p.m. |
|
Prof. Dr. Isabel Gonzalez-Alvarez Closing of Webinar |
2:50–2:55 p.m. |
Webinar Chair and Speakers:
- Prof. Dr. Isabel Gonzalez-Alvarez (Chair), Miguel Hernandez University, Pharmaceutics and Pharmaceutical Technology, Spain;
- Dr. Bart Hens, Drug Product Design Biomodeler/Biopharmaceutics Principal, Pfizer, United Kingdom;
- Dr. Marival Bermejo, Miguel Hernandez University, Pharmacokinetics and Pharmaceutical Technology, Spain;
- Dr. Yasuhiro (Hiro) Tsume, Merck Research Laboratories, New Jersey, United States of America.
